{"id":68887,"date":"2026-03-02T09:46:41","date_gmt":"2026-03-02T09:46:41","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=68887"},"modified":"2026-05-21T07:03:44","modified_gmt":"2026-05-21T07:03:44","slug":"pt-141","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/pt-141\/","title":{"rendered":"PT-141"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is PT-141?<\/h3>\n

PT-141 (bremelanotide)<\/strong> is a synthetic melanocortin receptor agonist acting at the MC4R<\/strong> in the central nervous system. Unlike PDE5 inhibitors that target vascular physiology, PT-141 activates CNS arousal pathways via dopamine release in the medial preoptic area. It is FDA-approved under the trade name Vyleesi for female hypoactive sexual desire disorder (not the research-use-only form sold here). Supplied in 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

What you get with MedsBase:<\/strong> Research-grade lyophilized peptides \u00b7 HPLC \u226599% purity (COA on request) \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide peptide courier \u00b7 1,400+ verified customer reviews<\/a><\/div>\n

\ud83d\udce6 Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days, we reship it.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specification<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS Number<\/strong><\/td>\n189691-06-3<\/td>\n<\/tr>\n
Molecular Formula<\/strong><\/td>\nC50<\/sub>H68<\/sub>N14<\/sub>O10<\/sub><\/td>\n<\/tr>\n
Molecular Weight<\/strong><\/td>\n1025.18 Da<\/td>\n<\/tr>\n
Sequence<\/strong><\/td>\nAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyophilized powder (or as supplied)<\/td>\n<\/tr>\n
Purity<\/strong><\/td>\n\u226599% (HPLC verified, COA on request)<\/td>\n<\/tr>\n
Storage<\/strong><\/td>\nLyophilized: 2\u20138\u00a0\u00b0C (refrigerator) for working stock; \u221220\u00a0\u00b0C for long-term storage of unopened vials. Reconstituted: 2\u20138\u00a0\u00b0C, use within ~30 days. Protect from light. Do not freeze\u2013thaw the reconstituted solution.<\/td>\n<\/tr>\n
Solubility<\/strong><\/td>\nBacteriostatic water (recommended) or sterile water for shorter use windows<\/td>\n<\/tr>\n
Research Use<\/strong><\/td>\nFor laboratory research use only. Not for human or veterinary diagnostic or therapeutic use.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is PT-141?<\/h2>\n

PT-141<\/strong> (international nonproprietary name: bremelanotide<\/strong>) is a synthetic seven-amino-acid cyclic peptide analog of alpha-melanocyte stimulating hormone (\u03b1-MSH). It belongs to the melanocortin<\/strong> family and was originally developed from studies of Melanotan II, which researchers noted produced unexpected arousal effects as a side effect during tanning-related research.<\/p>\n

Sequence (cyclic): Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Molecular weight approximately 1,025\u00a0Da. PT-141 binds melanocortin receptors with preference for the MC4 receptor (MC4R)<\/strong>, with measurable activity at MC1R, MC3R, and MC5R. The CNS-arousal research signal is attributed primarily to MC4R activation in the hypothalamic medial preoptic area.<\/p>\n

Bremelanotide was FDA-approved in June 2019 under the trade name Vyleesi<\/strong> specifically for generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The research-use-only form sold by peptide-research suppliers is chemically identical but is not<\/strong> the FDA-approved therapeutic product and is for laboratory research use only. For deeper mechanism and published research context, see our full PT-141 research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Central (Not Vascular) Arousal Pathway<\/h2>\n

PT-141’s most important mechanistic distinction is that it acts centrally<\/strong> \u2014 in the brain \u2014 rather than peripherally on vascular smooth muscle. This makes it fundamentally different from PDE5 inhibitors (Viagra, Cialis) which target the vascular nitric-oxide pathway to produce erection via blood-flow changes:<\/p>\n